INVVY - Indivior PLC

Other OTC - Other OTC Delayed Price. Currency in USD
2.7000
-0.2800 (-9.40%)
At close: 3:32PM EDT
Stock chart is not supported by your current browser
Previous Close2.9800
Open2.7500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.6000 - 2.7500
52 Week Range1.9750 - 23.9500
Volume42,577
Avg. Volume14,269
Market Cap379.979M
Beta (3Y Monthly)-0.68
PE Ratio (TTM)1.59
EPS (TTM)1.7000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-06-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters3 days ago

    Indivior loses appeal to block generic Suboxone opioid treatments

    The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.

  • Reuters4 days ago

    UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments

    A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.

  • Reckitt's Opioid Settlement Offers Some Relief
    Bloomberg5 days ago

    Reckitt's Opioid Settlement Offers Some Relief

    (Bloomberg Opinion) -- Reckitt Benckiser Plc has taken the medicine.The company has settled with U.S. authorities to resolve a long-running investigation into the sale and marketing of an opioid addiction treatment by former subsidiary Indivior Plc.The payment is a big one: $1.4 billion. That far exceeds the $400 million provision it had set aside. But it draws a line under an issue that had threatened to derail a potential break-up of the maker of Cillit Bang cleaner and Durex condoms. Reckitt denied any wrongdoing, and said the settlement was in the best interests of the company and investors.It certainly isn’t helpful to the company’s balance sheet – it will increase net debt to 2.8 times Ebitda at the end of this year, according to Martin Deboo, analyst at Jefferies. That further constrains the company’s ability to participate in industry M&A. However, the shares rose about 3% on Thursday. This indicates the outcome was no worse than feared. Analysts at Bernstein had suggested back in April, when Indivior was indicted by the Justice Department, that the worst case scenario could be $1.5 billion.What’s more, the settlement does not bar Reckitt from participating in U.S. government programs, such as one that provides free baby milk. Losing this would have been extremely damaging to the infant nutrition business that Reckitt added when it acquired Mead Johnson.But even more important is that by resolving the issue, Reckitt can now move forward unencumbered. Outgoing chief executive Rakesh Kapoor deserves credit for finalizing the matter before his departure, leaving a clean slate to his successor, Laxman Narasimhan.The potential liabilities threatened to hamper the logical conclusion of Reckitt’s separation into two divisions, one focused on household products, and the other on consumer health.Narasimhan will still face significant challenges when he arrives shortly. Chief among them is reinvigorating sales growth, which stalled under his predecessor. He must also determine whether Reckitt's industry-leading margins can be sustained, or whether some profitability must be sacrificed to step up investment and turbo charge sales growth.But at least he can now pursue a break-up – assuming he wants to – without the U.S. legal risks hanging over him.To contact the author of this story: Andrea Felsted at afelsted@bloomberg.netTo contact the editor responsible for this story: Jennifer Ryan at jryan13@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • PR Newswire5 days ago

    Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m

    SLOUGH, England and RICHMOND, Va. , July 11, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced revised expectations for FY 2019 net revenue and net income following stronger than expected H1 ...

  • Financial Times5 days ago

    Indivior raises guidance on strong performance of opioid treatment

    London-listed drugmaker Indivior has raised its guidance for this year’s earnings following the strong performance of a drug used to treat opioid addiction, sending shares up by more than a third. that Indivior’s former owner Reckitt Benckiser agreed to pay more than $1bn to resolve US investigations into how its former subsidiary marketed the drug Suboxone. Indivior said on Thursday that it now expects 2019 net revenue to be in the range of $670m to $720m, up from a previously forecast $525m to $575m.

  • Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes
    Reuters5 days ago

    Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

    The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.

  • Reuters5 days ago

    UPDATE 2-Reckitt to pay $1.4 bln to end Indivior probe

    Britain's Reckitt Benckiser will pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior. Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) to resolve the investigation into a business that was wholly demerged from the company in 2014. The U.S. Justice Department had accused Indivior of illegally boosting prescriptions for the opioid addiction treatment, called Suboxone Film.

  • Financial Times5 days ago

    Reckitt Benckiser to pay $1.4bn in US opioid penalty settlement

    Reckitt Benckiser has agreed to pay up to $1.4bn to US authorities in the largest penalty linked to the country’s opioid crisis. US authorities allege that the business, which Reckitt owned until 2014, made unsubstantiated claims about a new version of Suboxone, an anti-addiction drug, from 2006 to 2015. Reckitt spun out the subsidiary into a separate UK-listed company called Indivior in 2014.

  • Financial Times5 days ago

    Stocks to watch: Indivior, Hurricane Energy, Cobham, Natixis, BAT

    ● Reckitt Benckiser edged higher after it reached a deal with the US Department of Justice and Federal Trade Commission to exclude it from an investigation into alleged mis-selling of Suboxone film, an opiate addiction treatment, by its demerged business Indivior. “We think that the quick settlement is good news, as it provides clarity and protects RB’s US business from lengthy legal struggles,” said Kepler Cheuvreux. ● Indivior itself surged after reporting that sales of Suboxone film had held up in spite of generic competition entering the market in February.

  • Financial Times5 days ago

    Reckitt/opioid crisis: great to get straight

    Opioid addiction is costing Americans billions of dollars. It is not working out cheaply for Reckitt Benckiser either. A troublesome source of cost, doubt and distraction has evaporated before new boss Laxman Narasimhan takes over in September.

  • GlobeNewswire22 days ago

    DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Indivior PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Indivior PLC (“Indivior” or “the Company”) (OTC: INVVY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Indivior and its executives participated in a scheme to increase prescriptions of Suboxone Film.

  • ACCESSWIRE22 days ago

    FINAL DEADLINE ALERT - Indivior PLC (INVVY) Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: June 24, 2019

    NEW YORK, NY / ACCESSWIRE / June 24, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Indivior PLC ("Indivior" or the "Company") ...

  • GlobeNewswire22 days ago

    CLASS ACTION UPDATE for INVVY, MBNKF, XENT and ZUO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, June 24, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • GlobeNewswire22 days ago

    INDIVIOR 24 HOUR DEADLINE ALERT: APPROXIMATELY 24 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Indivior PLC - INVVY

    NEW ORLEANS, June 23, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large.

  • GlobeNewswire24 days ago

    ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Indivior PLC Investors of Final Deadline on Monday in Securities Class Action Commenced by the Firm – INVVY

    NEW YORK, June 22, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Indivior PLC (OTC: INVVY) from March 10, 2015 through.

  • Business Wire24 days ago

    INDIVIOR 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Indivior PLC - INVVY

    Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until June 24, 2019 to file lead plaintiff applications in a securities class action lawsuit against Indivior PLC (INVVY). Investor losses must relate to purchases of the Company’s securities between March 10, 2015 and April 9, 2019.

  • GlobeNewswire25 days ago

    Pawar Law Group Reminds Investors of June 24 Deadline in Securities Class Action Lawsuit Against Indivior PLC – INVVY

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Indivior PLC (INVVY) from March 10, 2015 through April 9, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Indivior investors under the federal securities laws. To join the Indivior class action, go to http://pawarlawgroup.com/cases/indivior-plc/ or call Vik Pawar, Esq.

  • GlobeNewswire25 days ago

    DEADLINE ALERT - Indivior PLC (INVVY) Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Plaintiff Deadline: June 24, 2019

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Indivior PLC (“Indivior” or the “Company”) (INVVY) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Indivior securities between March 10, 2015 and April 9, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On April 9, 2019, the U.S. Department of Justice (“DOJ”) announced that a federal grand jury had indicted Indivior “for engaging in an illicit nationwide scheme to increase prescriptions of Suboxone Film, an opioid drug used in the treatment of opioid addiction.” The indictment stated that Indivior misled “health care providers and health care benefit programs into believing that Suboxone Film was safer, less divertible, and less abusable than other opioid-addiction treatment drugs,” acquiring billions of dollars in revenue in Suboxone Film prescriptions.

  • GlobeNewswire25 days ago

    Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC

    Law Offices of Howard G. Smith reminds investors of the upcoming June 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Indivior PLC  (“Indivior” or the “Company”) (OTC: INVVY) securities between March 10, 2015 and April 9, 2019, inclusive (the “Class Period”). Investors suffering losses on their Indivior investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com. On April 9, 2019, the U.S. Department of Justice (“DOJ”) announced that a federal grand jury had indicted Indivior “for engaging in an illicit nationwide scheme to increase prescriptions of Suboxone Film, an opioid drug used in the treatment of opioid addiction.” According to the indictment, Indivior deceived “health care providers and health care benefit programs into believing that Suboxone Film was safer, less divertible, and less abusable than other opioid-addiction treatment drugs,” acquiring billions of dollars in revenue in Suboxone Film prescriptions.

  • ACCESSWIRE25 days ago

    Class Action Upcoming Deadline - S, BSX & INVVY - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / June 21, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • ACCESSWIRE25 days ago

    FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Indivior PLC and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 21, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Indivior PLC ("Indivior" or "the Company") (OTC PINK: INVVY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 10, 2015 and April 9, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before June 24, 2019.

  • GlobeNewswire25 days ago

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BE, INVVY, MBNKF and KSHB

    The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • GlobeNewswire26 days ago

    Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Indivior PLC  (“Indivior” or the “Company”) (OTC: INVVY) investors who purchased securities between March 10, 2015 and April 9, 2019, inclusive (the “Class Period”). If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On April 9, 2019, the U.S. Department of Justice (“DOJ”) announced that a federal grand jury had indicted Indivior “for engaging in an illicit nationwide scheme to increase prescriptions of Suboxone Film, an opioid drug used in the treatment of opioid addiction.” According to the indictment, Indivior deceived “health care providers and health care benefit programs into believing that Suboxone Film was safer, less divertible, and less abusable than other opioid-addiction treatment drugs,” acquiring billions of dollars in revenue in Suboxone Film prescriptions.